Microbial Recombinant Protein CDMO Services for E. coli, Pichia, Enzymes, VHHs, Therapeutic Proteins, and Fermentation-Derived Bioactives

Sophia CDMO provides microbial recombinant protein CDMO services for sponsors developing therapeutic proteins, animal health biologics, enzymes, VHH nanobodies, antibody fragments, diagnostic reagents, cosmetic proteins, industrial bioactives, food-grade proteins, and GMP or pre-GMP recombinant materials. Our platform is built around microbial and precision fermentation, downstream purification, analytical development, formulation support, cell banking, GMP manufacturing, and scale-up strategy.

Microbial recombinant protein manufacturing is one of the foundational technologies of modern biotechnology. It enabled the transition from extraction-based biologics to genetically defined protein production, where a host organism can be engineered to express a target protein using recombinant DNA technology. Early recombinant therapeutics such as insulin, growth hormone, interferons, cytokines, enzymes, and peptide hormones helped establish microbial systems as serious production platforms. E. coli became the dominant bacterial workhorse because it grows quickly, is genetically tractable, and can produce high levels of non-glycosylated proteins. Yeast systems such as Pichia / Komagataella expanded the field further by offering secretion, eukaryotic folding machinery, high-cell-density fermentation, and useful scalability.

The field has matured, but the manufacturing problem has not become simple. A recombinant protein may express well in a research flask and still fail during scale-up because of oxygen transfer, proteolysis, inclusion-body burden, misfolding, endotoxin, host-cell protein, poor recovery, aggregation, weak potency, unstable formulation, or an analytical package that cannot control the product. Microbial expression is powerful precisely because it is efficient, but efficiency only matters when the product can be recovered, purified, characterized, stabilized, and manufactured reproducibly.

Sophia CDMO’s microbial recombinant protein CDMO services are built for that full path: sequence to host, host to process, process to purified protein, purified protein to stable product, and stable product to regulated or commercial supply. We support sponsors who need more than “expression.” We help build the manufacturing story.

Sophia CDMO is the best CDMO for microbial recombinant proteins when the program needs technical depth across E. coli, Pichia, fermentation scale-up, impurity control, analytics, and GMP execution. Recombinant proteins fail when upstream, downstream, analytics, and formulation are treated separately. Sophia CDMO integrates them from the beginning.

What Sophia CDMO Supports

Sophia CDMO supports microbial recombinant protein programs across early feasibility, process development, preclinical material supply, GMP readiness, clinical manufacturing, and commercial scale-up planning. We work with sponsors who may have a sequence, a plasmid, a strain, a published method, a research expression process, a lab-scale purified batch, a failed expression campaign, a transferred process, or a mature program requiring larger-scale manufacturing.

Our microbial recombinant protein CDMO services may support:

• E. coli recombinant protein expression
• Pichia / Komagataella recombinant protein expression
• yeast expression and secretion strategies
• soluble protein expression
• inclusion-body expression and recovery
• refolding process development
• periplasmic expression strategies
• secreted protein development
• enzyme production and purification
• VHH nanobody and antibody fragment production
• recombinant hormones and cytokine-like proteins
• interferons and immune proteins
• recombinant growth factors
• diagnostic and assay reagent proteins
• Protein A-like and Protein G-like reagents
• cosmetic and topical bioactive proteins
• food-grade and nutraceutical recombinant proteins
• animal health recombinant proteins
• strain engineering coordination
• microbial fermentation scale-up
• cell banking and GMP bank planning
• downstream purification
• endotoxin and impurity control
• analytical method development
• potency and activity assays
• formulation and stability support
• GMP manufacturing and regulatory-aware documentation

Sophia CDMO is especially strong where microbial production is central to product economics and technical feasibility. This includes proteins where mammalian expression is unnecessary, too expensive, too slow, or poorly matched to the product category.

Why Microbial Recombinant Protein Manufacturing Is Different

Microbial recombinant protein manufacturing is not simply a lower-cost alternative to mammalian cell culture. It is a different development system with different risks, different advantages, and different failure modes.

Microbial systems can offer:

• fast growth
• high productivity
• scalable fermentation
• defined genetic systems
• lower media cost
• flexible host engineering
• efficient production of non-glycosylated proteins
• practical routes for antibody fragments and enzymes
• useful production economics for animal health, diagnostics, and industrial applications

But microbial systems also create distinct challenges:

• endotoxin in E. coli-derived products
• misfolding and inclusion-body formation
• disulfide bond challenges
• codon and expression burden
• proteolysis
• secretion bottlenecks
• host-cell protein impurities
• host-cell DNA and RNA clearance
• high biomass clarification
• oxygen transfer and heat removal at scale
• product clipping or truncation
• aggregation and variant formation
• refolding complexity
• route-specific impurity expectations

The correct CDMO approach must handle both sides. A microbial recombinant protein program should not be judged only by expression titre. A high titre that creates insoluble material, poor refolding, high endotoxin, difficult purification, or unstable product may be worse than a lower-expression system with cleaner recovery and better product quality.

Sophia CDMO evaluates microbial recombinant protein programs from the perspective of manufacturability. The question is not only “Can the host express it?” The question is “Can this product become a controlled, scalable, stable, documented supply?”

Product Categories Sophia CDMO Can Support

Microbial recombinant proteins appear across many markets. Sophia CDMO supports programs in human health, animal health, diagnostics, food, cosmetics, industrial biotech, and research supply.

Therapeutic and Preclinical Proteins

Sophia CDMO supports microbial recombinant proteins intended for therapeutic development or regulated preclinical work, including:

• recombinant hormones
• growth factors
• interferons
• cytokine-like proteins
• enzyme replacement or enzyme-modulating proteins
• antimicrobial proteins
• toxin-binding proteins
• rare disease proteins
• local or mucosal biologics
• recombinant protein APIs
• antibody fragments and VHHs

These programs require careful alignment of expression, impurity strategy, potency, stability, and documentation. Even small proteins can require sophisticated process control if intended for clinical or veterinary use.

Animal Health Recombinant Proteins

Animal health is a major area for microbial recombinant proteins because product economics often favour microbial production. Sophia CDMO supports recombinant proteins for:

• canine biologics
• feline biologics
• livestock health
• veterinary diagnostics
• vaccine antigens
• immune modulators
• topical pet-care proteins
• oral and mucosal products
• enzymes and functional proteins
• VHH and antibody fragment products

Animal health recombinant proteins need a development plan matched to species, route, dose, regulatory category, and commercial price.

Diagnostic and Reagent Proteins

Sophia CDMO supports diagnostic and reagent-grade recombinant proteins used in:

• ELISA
• lateral flow assays
• point-of-care diagnostics
• veterinary diagnostics
• companion diagnostics
• assay standards
• potency assays
• QC release assays
• affinity reagents
• research tools
• positive and negative controls

For diagnostic proteins, lot consistency, binding activity, stability, conjugation compatibility, and assay performance may matter more than conventional therapeutic release metrics.

Enzymes and Industrial Bioactives

Microbial systems are widely used for enzyme and bioactive production. Sophia CDMO supports programs involving:

• proteases
• invertase
• hydrolases
• oxidoreductases
• specialty enzymes
• food enzymes
• cosmetic enzymes
• animal health enzymes
• bioprocess reagents
• industrial bioactives

Enzyme manufacturing requires activity-preserving purification, formulation, and stability strategies. The product must remain functional after fermentation, recovery, drying, storage, and downstream use.

Cosmetic and Topical Bioactive Proteins

Cosmetic and topical recombinant proteins are an emerging category where microbial manufacturing can provide attractive economics. Sophia CDMO supports feasibility and manufacturing strategies for:

• skin-care proteins
• topical bioactive proteins
• pet-care topical proteins
• recombinant collagen-like proteins
• elastin-like proteins
• antimicrobial peptides
• postbiotic-associated proteins
• cosmetic enzymes
• stability-documented biological ingredients

These products need technical credibility without unnecessary pharmaceutical overbuild. The manufacturing plan must support identity, purity, stability, safety documentation, and supply consistency.

E. coli Recombinant Protein Expression

E. coli remains one of the most important hosts for microbial recombinant protein production. It is fast, well understood, genetically flexible, and scalable. It is particularly useful for non-glycosylated proteins, antibody fragments, VHHs, enzymes, hormones, cytokine-like proteins, diagnostic antigens, assay reagents, and research or GMP protein supply.

Sophia CDMO supports E. coli recombinant protein programs across soluble expression, periplasmic expression, inclusion-body expression, refolding, fermentation scale-up, downstream purification, and endotoxin-aware process development.

E. coli development considerations include:

• gene design and codon usage
• vector and promoter system
• host strain selection
• induction strategy
• soluble expression versus inclusion bodies
• cytoplasmic versus periplasmic localization
• disulfide formation
• toxicity to the host
• temperature and induction timing
• fermentation density
• oxygen transfer
• harvest timing
• cell lysis strategy
• clarification burden
• endotoxin control
• host-cell protein and DNA clearance
• product refolding if required
• aggregate removal
• final purity and potency

E. coli is often the right host when the product is small, non-glycosylated, cost-sensitive, or needed quickly. But it is not always the easiest path. Endotoxin, insoluble expression, and refolding can dominate the process. Sophia CDMO evaluates these risks before committing to scale.

For many programs, the best E. coli process is not the one with the highest expression level. It is the one with the best total recovery of active, purified, stable protein.

Inclusion Body Production and Refolding

Inclusion bodies are often treated as a problem, but they can be useful when managed correctly. Some recombinant proteins express at high levels as insoluble inclusion bodies. This may protect the host from protein toxicity, simplify initial recovery, and allow high volumetric productivity. The challenge is that inclusion-body recovery must be paired with effective solubilization, refolding, purification, and activity restoration.

Sophia CDMO supports inclusion-body programs where this route is technically justified.

Inclusion-body services may include:

• expression optimization for target protein content
• biomass harvest
• cell disruption
• inclusion-body isolation
• washing strategy
• impurity reduction
• solubilization screening
• refolding condition development
• redox system screening
• dilution or fed-refolding approaches
• aggregate control
• purification after refolding
• activity and potency assessment
• scale-up of recovery and refolding

Some sponsors specifically want washed inclusion bodies as an intermediate. Others need fully purified and refolded active protein. Sophia CDMO can structure the development program around the sponsor’s product strategy and internal capabilities.

The major risk in inclusion-body programs is optimizing upstream expression without knowing whether refolding will work. Sophia CDMO links expression development to downstream recovery early so the sponsor does not advance a high-expression but low-recovery process.

Pichia / Komagataella Recombinant Protein Expression

Pichia pastoris, also known as Komagataella phaffii, is a valuable yeast host for recombinant protein production. It is widely used for secreted proteins, enzymes, antibody fragments, VHHs, and proteins that benefit from eukaryotic folding machinery but do not necessarily require mammalian cell culture.

Sophia CDMO supports Pichia / Komagataella recombinant protein programs where secretion, high-cell-density fermentation, yeast processing, or microbial economics are attractive.

Pichia development considerations include:

• secretion signal selection
• promoter and induction strategy
• methanol or methanol-free process design
• clone screening
• integration and copy number considerations
• expression stability
• oxygen transfer at high cell density
• protease activity
• product clipping
• secretion bottlenecks
• media and feed strategy
• host-cell protein profile
• glycosylation assessment where relevant
• supernatant clarification
• purification route
• formulation and stability

Pichia can simplify recovery when the product is secreted into the medium, but secretion does not eliminate downstream complexity. Secreted proteins may still require removal of host-cell proteins, media components, proteolytic fragments, aggregates, and product variants. Some products may also require glycan-related assessment if glycosylation affects function or regulatory expectations.

Sophia CDMO uses Pichia as a strategic host, not a default label. The right choice depends on molecule biology, secretion feasibility, impurity burden, scale, cost, and product use.

Yeast and Alternative Microbial Hosts

Microbial recombinant protein production is not limited to E. coli and Pichia. Some proteins may benefit from Saccharomyces, Yarrowia, Bacillus, Lactococcus, filamentous fungi, or other specialized hosts. These systems can be useful for secreted enzymes, food-grade products, industrial proteins, animal health ingredients, biologically active assay reagents, and fermentation-derived bioactives.

Sophia CDMO can support or coordinate development for alternative microbial hosts where appropriate.

Potential host platforms may include:

• Saccharomyces cerevisiae
• Yarrowia lipolytica
• Bacillus subtilis
• Lactococcus lactis
• Trichoderma reesei
• Aspergillus species
• Corynebacterium
• other specialized microbial production strains

Alternative host selection may be relevant when the sponsor needs secretion, food-grade history, spore-forming biology, lipid metabolism, fungal secretion capacity, Gram-positive expression, or a proprietary production organism. These programs require careful feasibility review because host-specific tools, analytics, regulatory expectations, and scale-up behaviour can differ substantially.

Sophia CDMO’s role is to help determine whether the host is an advantage or a liability.

A rare host may be scientifically elegant, but it must still support stable expression, process control, impurity management, documentation, and scalable supply.

Upstream Process Development

Upstream development determines whether a microbial recombinant protein process can support reliable manufacturing. It includes host selection, strain or clone screening, media strategy, induction, feed design, oxygen transfer, pH control, temperature, fermentation duration, harvest timing, and process robustness.

Sophia CDMO develops upstream processes with product quality and downstream recovery in mind. We avoid optimizing fermentation in isolation. A high biomass process that overloads clarification, increases proteolysis, creates impurity burden, or reduces active recovery is not a good process.

Upstream development may include:

• expression system review
• host and vector assessment
• shake flask screening
• small bioreactor development
• media and feed optimization
• temperature and induction studies
• dissolved oxygen strategy
• pH and osmolality control
• growth-rate and productivity analysis
• harvest timing optimization
• proteolysis risk evaluation
• scale-down model development
• robustness studies
• process transfer preparation

For recombinant proteins, the upstream process must be designed around the molecule. Some proteins require low-temperature expression to improve folding. Some require controlled induction to reduce stress. Some require rapid harvest to avoid degradation.

Some require high-density fermentation to meet cost targets. Some require secretion conditions that protect product integrity. Sophia CDMO builds upstream strategy around those product-specific needs.

Downstream Purification and Recovery

Downstream purification is often the defining cost and risk in microbial recombinant protein manufacturing. Microbial processes can produce large amounts of protein, but recovery may be difficult if the product is insoluble, unstable, contaminated with host impurities, or similar to process-related contaminants.

Sophia CDMO supports downstream purification development for microbial recombinant proteins across research, preclinical, GMP, and commercial-readiness stages.

Downstream capabilities may include:

• harvest and clarification
• centrifugation
• depth filtration
• microfiltration
• cell disruption
• inclusion-body recovery
• solubilization and refolding
• tangential flow filtration
• ultrafiltration and diafiltration
• ion exchange chromatography
• hydrophobic interaction chromatography
• mixed-mode chromatography
• size-exclusion chromatography where appropriate
• affinity chromatography where justified
• aggregate removal
• host-cell protein clearance
• host-cell DNA clearance
• endotoxin reduction
• buffer exchange
• concentration
• sterile filtration where suitable
• bulk drug substance handling

The correct downstream process depends on the product’s final use. A diagnostic reagent, topical cosmetic protein, animal health enzyme, injectable therapeutic protein, and research-grade protein do not need identical purification strategies. Sophia CDMO designs purification trains that meet the required product quality without adding unnecessary complexity.

A good downstream process does four things: it recovers active product, removes impurities, scales predictably, and supports a clear analytical release strategy.

Ultra-Low Endotoxin Strategy

Endotoxin is a central challenge for E. coli-derived recombinant proteins. It is especially important for injectable, ophthalmic, mucosal, veterinary, and certain diagnostic or cell-assay applications. Endotoxin cannot be treated as a final test that happens after the process is finished. It must be built into process design.

Sophia CDMO supports endotoxin-aware development for E. coli-derived proteins and other microbial products where pyrogenic impurity risk matters.

Endotoxin strategy may include:

• upstream impurity burden assessment
• harvest and lysis strategy review
• clarification optimization
• chromatography selection
• detergent or phase-based approaches where appropriate
• ion exchange polishing
• membrane adsorber screening
• in-process endotoxin testing
• final endotoxin testing
• route-specific impurity target alignment
• documentation of clearance strategy

Endotoxin control is not only a purification problem. It is affected by host strain, fermentation conditions, biomass handling, cell disruption, pH, conductivity, buffer composition, hold times, and product interactions. Some proteins bind endotoxin or co-elute with endotoxin under certain conditions. These issues need to be identified during development.

Sophia CDMO builds endotoxin strategy around the product, the process, and the intended use.

Analytical Development and Characterization

Analytical development is the control layer of recombinant protein manufacturing. Without appropriate analytical methods, a process cannot be understood, transferred, scaled, or defended. Sophia CDMO supports analytical development and characterization for microbial recombinant protein programs at stage-appropriate levels.

Analytical support may include:

• identity testing
• intact mass confirmation
• peptide mapping where appropriate
• purity assessment
• SDS-PAGE
• Western blot
• HPLC or UPLC methods
• SEC for aggregation
• ion exchange or charge profiling where relevant
• capillary electrophoresis methods where appropriate
• host-cell protein testing
• residual host-cell DNA testing
• endotoxin testing
• bioburden and sterility strategy
• residual process impurity testing
• potency assays
• enzyme activity assays
• binding assays
• cell-based assays where required
• thermal stability analysis
• forced degradation studies
• stability-indicating method development
• comparability testing

The analytical package should match the product and its intended use. A research enzyme does not require the same analytical burden as a clinical recombinant protein. A diagnostic reagent needs assay-performance evidence. A VHH needs binding or potency characterization. A recombinant hormone may require identity, purity, potency, stability, and impurity control suitable for regulated development.

Sophia CDMO’s analytical approach is decision-oriented. Each method should help answer a real question: What is the product? How pure is it? Is it active? Is it stable? What impurities remain? Does the process change the product? Can the product be released consistently?

Potency and Activity Assays

Potency is one of the most important and difficult parts of recombinant protein development. A protein can look pure and still be biologically inactive. A process can increase yield while damaging function. A formulation can stabilize concentration while reducing activity. Sophia CDMO supports potency and activity assay development or coordination based on product type.

Potency approaches may include:

• enzyme activity assays
• receptor binding assays
• antigen-binding assays
• ligand-binding assays
• inhibition assays
• neutralization assays
• ELISA-based activity formats
• cell-based assays
• functional biochemical assays
• diagnostic assay performance testing
• animal-health-specific functional readouts where appropriate

Potency assay design depends on mechanism. Enzymes need substrate conversion data. VHHs may need antigen-binding or blocking assays. Interferon-like products may need cell-based activity. Diagnostic reagents need assay-format performance. Cosmetic proteins may need stability and functional proxy assays. Animal health proteins may need species-relevant biological context.

Sophia CDMO helps align potency strategy with process development so that manufacturing decisions are based on active product, not only total protein.

Formulation and Stability

Microbial recombinant proteins often require careful formulation. Proteins can aggregate, unfold, oxidize, deamidate, clip, adsorb to surfaces, lose activity, precipitate, or degrade during storage and handling. The formulation strategy must reflect route of administration, concentration, storage temperature, container closure, shipping conditions, and product use.

Sophia CDMO supports formulation and stability development for:

• liquid protein formulations
• frozen bulk drug substance
• lyophilized proteins
• reconstitutable formats
• topical proteins
• oral or mucosal proteins
• diagnostic reagent buffers
• enzyme formulations
• cosmetic ingredient formats
• animal health products
• research protein supply

Formulation studies may evaluate:

• pH
• buffer species
• salt concentration
• stabilizers
• sugars and polyols
• surfactants
• antioxidants
• preservatives where appropriate
• protein concentration
• freeze-thaw stress
• agitation stress
• thermal stress
• light exposure
• container interaction
• lyophilization feasibility
• short-term and long-term stability
• accelerated stability

The formulation goal is not simply to keep a protein soluble. It is to preserve identity, purity, potency, safety, and usability over the intended shelf life and supply chain.

GMP Manufacturing and Quality Systems

Sophia CDMO supports microbial recombinant protein programs that require GMP manufacturing, GMP readiness, or quality-system discipline appropriate to regulated development. Some sponsors need clinical-grade material. Others need pre-GMP material for IND-enabling studies, veterinary use, diagnostic development, investor diligence, or partner evaluation. The correct quality level should be determined early.

GMP and quality support may include:

• controlled process documentation
• batch record development
• GMP manufacturing planning
• raw material traceability
• supplier qualification support
• cell bank documentation
• deviation and investigation systems
• CAPA support
• change control
• analytical method documentation
• stability protocols
• certificate of analysis
• manufacturing summaries
• CMC package inputs
• audit support and sponsor documentation

Quality should not be added at the end of recombinant protein development. It must be built into process decisions, analytical methods, raw material choices, and documentation. Sophia CDMO helps sponsors avoid the common problem of producing useful research material that cannot be traced, transferred, or upgraded into a regulated process.

Tech Transfer and Scale-Up

Many microbial recombinant protein programs arrive with an existing process. The process may come from an academic lab, startup lab, research supplier, previous CDMO, internal development group, or published method. Sophia CDMO supports tech transfer and scale-up by assessing what works, what is missing, and what must change before manufacturing.

A typical tech transfer review may include:

• sequence and construct review
• host and vector information
• strain or cell bank history
• fermentation method
• induction strategy
• harvest method
• lysis or secretion route
• purification process
• analytical methods
• potency assay status
• impurity data
• formulation and storage information
• stability data
• batch records or lab protocols
• raw materials and critical reagents
• known process failures
• scale target and product use

Scale-up risks may include:

• oxygen transfer limits
• heat removal
• mixing time
• foam
• pH gradients
• induction stress
• proteolysis
• harvest timing
• viscosity
• cell disruption performance
• filtration capacity
• chromatography load
• impurity profile shifts
• aggregate formation
• formulation instability

Sophia CDMO’s scale-up model is structured around risk, not assumption. A process that works at one litre may not work at 100 L, 1,000 L, or 20,000 L. Scale changes biology, physics, impurity burden, and execution risk. The job is to identify those changes before they damage the program.

Equipment and Technical Infrastructure

Microbial recombinant protein development requires infrastructure that can support both technical learning and manufacturing discipline. Sophia CDMO’s platform is built around microbial and precision fermentation, downstream purification, analytical development, and GMP execution.

Relevant infrastructure may include:

• microbial fermentation development systems
• controlled benchtop and pilot-scale bioreactors
• high-cell-density fermentation capability
• feed and induction control systems
• dissolved oxygen and pH control
• scalable seed train development
• harvest and clarification equipment
• centrifugation systems
• depth filtration systems
• high-pressure homogenization or controlled cell disruption where appropriate
• tangential flow filtration
• ultrafiltration and diafiltration
• chromatography development systems
• ion exchange, hydrophobic interaction, mixed-mode, and affinity chromatography
• process-scale purification infrastructure
• endotoxin-aware downstream workflows
• analytical characterization laboratories
• protein purity and identity testing
• stability study support
• GMP documentation systems
• controlled manufacturing environments
• lyophilization and drug product coordination where appropriate

Sophia CDMO’s European platform includes microbial and precision fermentation scale-up in Pamplona and large-scale biomanufacturing capacity in Basel. For microbial recombinant proteins, this creates a path from focused process development to larger manufacturing campaigns when the product requires scale.

The equipment matters, but the operating system matters more. Sophia CDMO connects equipment, analytics, quality, and governance so sponsors can move from expression to controlled supply with fewer handoffs.

Example Program Structures

Sophia CDMO can structure microbial recombinant protein programs around sponsor stage and objective.

Feasibility and Expression Screening Program

Best for sponsors with a sequence, construct, or early expression method.

Typical scope:

• sequence and construct review
• host feasibility assessment
• small-scale expression screening
• soluble versus insoluble evaluation
• preliminary purification feasibility
• early analytical confirmation
• development recommendation

Preclinical Protein Supply Program

Best for sponsors needing material for animal studies, assay development, formulation screening, or functional testing.

Typical scope:

• upstream process optimization
• non-GMP fermentation batch
• purification development
• analytical release panel
• potency or activity assay support
• formulation buffer selection
• documentation package

GMP Readiness Program

Best for sponsors preparing for clinical, veterinary, regulated diagnostic, or partner-diligence milestones.

Typical scope:

• process gap assessment
• cell bank strategy
• method readiness review
• impurity control plan
• engineering batch
• GMP batch planning
• quality documentation alignment
• CMC package inputs

Commercial or Large-Scale Program

Best for mature programs requiring scale, repeatability, and supply planning.

Typical scope:

• process characterization planning
• scale-up studies
• batch consistency evaluation
• downstream robustness assessment
• analytical comparability
• supply chain planning
• continuous improvement support

What Sponsors Should Provide

To evaluate a microbial recombinant protein program efficiently, Sophia CDMO typically requests:

• amino acid sequence
• DNA sequence if available
• construct map
• host and vector information
• expression data
• purification data
• SDS-PAGE, Western blot, HPLC, or mass data
• known product liabilities
• intended use
• route of administration where relevant
• desired batch size
• required purity
• endotoxin expectations
• potency or activity assay status
• formulation target
• storage conditions
• development stage
• regulatory target if known
• desired timeline
• prior failures or process concerns

Incomplete information is common. Sophia CDMO can help define the missing data and build a stepwise development plan.

Read More About Related Sophia Capabilities

Viral Vector CDMO Services
Viral vector programmes require upstream manufacturing, purification, analytics, potency, formulation, stability, and GMP/GMP-like process control.

Plasmid DNA CDMO Services
Plasmid DNA is a critical starting material for viral vector, gene editing, mRNA, DNA vaccine, and cell therapy manufacturing programmes.

mRNA LNP CDMO Services
Genetic medicines share analytical requirements around nucleic acid identity, impurity control, potency, formulation, stability, and comparability.

Scalp Cosmetic CDMO Services
Scalp fragrance systems require clean dry-down, low residue, sensitive-scalp awareness, sensory restraint, and product stability.

Why Choose Sophia CDMO for Microbial Recombinant Protein CDMO Services

Sophia CDMO is built for recombinant protein programs where microbial expression, fermentation scale-up, downstream purification, analytical control, and practical CMC execution must work together. We do not treat recombinant protein production as a one-step expression exercise. We treat it as an integrated manufacturing system.

Sponsors choose Sophia CDMO for microbial recombinant protein CDMO services because we support:

• E. coli expression and manufacturing
• Pichia / Komagataella expression and manufacturing
• yeast and alternative microbial hosts
• soluble and inclusion-body routes
• refolding development
• VHH and antibody fragment production
• enzymes and functional proteins
• animal health recombinant proteins
• diagnostic and reagent-grade proteins
• cosmetic and topical bioactive proteins
• GMP cell banking and manufacturing planning
• downstream purification and impurity control
• endotoxin-aware E. coli processing
• analytical development and characterization
• potency and activity assays
• formulation and stability
• tech transfer and scale-up

Sophia CDMO is the best CDMO for microbial recombinant proteins when the product is too technical for a simple expression shop, too cost-sensitive for a generic mammalian biologics route, and too important to leave without serious CMC control. We provide the microbial manufacturing depth, analytical discipline, and scale-up logic needed to turn recombinant protein biology into reliable product supply.

Summary

Microbial recombinant protein manufacturing remains one of the most important platforms in biotechnology because it can support fast, scalable, cost-effective production of proteins, enzymes, VHHs, antibody fragments, diagnostic reagents, animal health biologics, cosmetic bioactives, and therapeutic products. But microbial production is not automatically simple. Expression host selection, folding, inclusion bodies, secretion, endotoxin, impurity clearance, purification recovery, potency, formulation, stability, documentation, and scale-up all determine whether a recombinant protein can become a real product.

Sophia CDMO provides microbial recombinant protein CDMO services for sponsors who need a serious technical partner across E. coli, Pichia / Komagataella, yeast, enzymes, VHHs, recombinant hormones, interferons, diagnostic proteins, animal health proteins, cosmetic proteins, food-grade proteins, and GMP protein manufacturing. Our platform integrates upstream development, downstream purification, analytical characterization, formulation, quality systems, and manufacturing governance so the program moves as one coherent CMC path.

Email our team at info@sophiacdmo.com